Relay Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Relay Therapeutics, Inc. | RLAY - NASDAQ |
$18.00-$19.00 | $20.00 | $35.00 | 20 million | 7/16/2020 |
| JP Morgan, Goldman Sachs, Cowen, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-06-24 Terms Added 2020-07-09 Terms Changed 2020-07-15 | ||||||
Relay Therapeutics, Inc. Quote & Chart - Click for current quote - RLAY
IPO Boutique aggregates information on public companies and private companies, such as "RLAY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Relay Therapeutics, Inc. (adapted from Relay Therapeutics, Inc. prospectus):
They are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RLAY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.